A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Summary

This is a single arm, open-label, single center study evaluating the safety, feasibility, clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell carcinoma. Ten patients will be treated. The goal is for GLA-SE to assist the patient's own immune system in attacking the cancer cells.

Timeline

Start

2014-01

Primary completion

2018-03

Completion

2018-03

Drugs

Indications